Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine CandidateBusiness Wire • 09/15/21
Oragenics's New Preclinical Data Supports Its Approach For COVID-19 Vaccine DevelopmentBenzinga • 08/30/21
Oragenics' SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal AdjuvantsBusiness Wire • 08/30/21
Oragenics Stock Is Trading Higher On Licensing, Material Transfer Pact For Rapid Development Of COVID-19 VaccineBenzinga • 07/27/21
Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 VaccinesBusiness Wire • 07/27/21
Oragenics: 2 New Phase 1 Trials Should Resurrect Investor Sentiment, Driving Upside By 2022Seeking Alpha • 05/09/21
Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 VaccineBusiness Wire • 03/09/21
